Joint Clinical Trials Office
A Phase Ib Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 2, 2023
APEC1621C NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE) SCREENING PROTOCOL
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 2, 2023
Phase 1 study of venetoclax/azacitidine or venetoclax in combination with ziftomenib (KO-539) or standard induction cytarabine/daunorubicin (7+3) chemotherapy in combination with ziftomenib for the treatment of patients with acute myeloid leukemia
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 11, 2023
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 17, 2023
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 17, 2023
A Phase 2 Study of Ipatasertib in Combination with Pembrolizumab for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
Study Status:
Open to Enrollment
Primary Investigator:
Date: November 3, 2023
Randomized Phase 2 Study of daunorubicin and cytarabine liposome + Pomalidomide versus daunorubicin and cytarabine liposome in Newly Diagnosed AML with MDS-Related Changes
Study Status:
Open to Enrollment
Primary Investigator:
Date: November 3, 2023
A Phase 2b, multicenter, randomized, double-blind study of safety and efficacy of TAK-755 (rADAMTS13) with minimal to no plasma exchange (PEX) in the treatment of immune-mediated thrombotic thrombocytopenic purpura (iTTP)
Study Status:
Open to Enrollment
Primary Investigator:
Date: November 7, 2023
A Phase 1, Open-Label, Safety, Tolerability, and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
Study Status:
Open to Enrollment
Primary Investigator:
Date: November 7, 2023
A phase IIa randomized, double-blinded clinical trial of naproxen or aspirin for cancer immune interception in Lynch syndrome
Study Status:
Open to Enrollment
Primary Investigator:
Date: November 8, 2023